We're proud to partner with advisors from organizations that share our mission to support quality-driven NASH care delivery.
baylor college of medicine
Norman Sussman, MD
Dr. Norman L. Sussman is an active member of Baylor St. Luke’s Liver Center. He is Board Certified in Internal Medicine, Gastroenterology, and Transplant Hepatology. His clinical interests cover all aspects of liver disease, and his research interests include assessment and management of acute liver failure, artificial liver support, new agents to treat viral hepatitis, and complications of advanced cirrhosis.
Fasiha Kanwal, MD, MSHS
Dr. Fasiha Kanwal is a gastroenterologist at Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, and associate professor of medicine in the department of medicine at Baylor College of Medicine, both in Houston, Texas.
Douglas Dieterich, MD
Dr. Douglas Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY. He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.
Dr. Dieterich is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B, C, and NASH.
Amon Asgharpour, MD
Dr. Amon Asgharpour is an Assistant Professor in the Department of Medicine, Division of Liver Diseases. He is board certified in Internal Medicine and Gastroenterology.
He is the author of a multitude of publications and his research at Mount Sinai will focus on clinical trials and translational research in nonalcoholic fatty liver disease and steatohepatitis.
Amreen dinani, MD
Amreen Dinani, MD, is an Assistant Professor in the Department of Medicine, Division of Liver Diseases.
Dr. Dinani is a member of many professional societies including American College of Gastroenterology and American Association of the Study of Liver Diseases. She introduced non-invasive markers of liver fibrosis and vibration controlled transient elastogrpahy (VCTE) during her 4 year tenure at Dartmouth Hitchcock Medical Centre, Lebanon, New Hampshire.
Mary Rinella, MD
Dr. Mary Rinella is a Professor of Medicine at Northwestern University’s Feinberg School of Medicine. She studied basic mechanisms of steatohepatitis with the support of the American Gastroenterological Association and the National Institutes of Health for ten years.
Currently, her focus is on clinical research in the area of nonalcoholic fatty liver disease/NASH both before and after liver transplantation. Her primary clinical focus within the NASH realm is on the associations between NASH and cardiovascular disease and the occurrence of NASH after liver transplantation. She is the Director of the Northwestern Fatty Liver Program and currently serves as Chair of the NAFLD/NASH Special Interest Group at the American Association for the Study of Liver Diseases.
OCHSNER health system
George Therapondos, MD
Dr. George Therapondos is currently the Hepatology Section Head at the Ochsner MultiOrgan Transplant Institute.
He was director of the Clinical Trials Unit of the Multi-organ Transplant Program of the University Health Network in Toronto, Canada and worked as Assistant Professor and Staff Hepatologist at Toronto General Hospital.
His most research interests have focused on adult deceased and living donor liver transplantation and quality of life issues in liver patients.
Nigel Girgrah, MD, PhD
Dr. Nigel Girgrah received both his MD and PhD at the University of Toronto. He has specialist certification in both gastroenterology and internal medicine with the Royal College of Physicians and Surgeons of Canada.
He served as Director of Education for the Multi-Organ Transplant Program at the University Health Network in Toronto for several years.
He completed further research training in Hepatology in the area of portal hypertension and his clinical expertise is in end-stage liver disease and transplant hepatology. Additional clinical and research areas of interest include recurrent viral disease post-liver transplantation and living donation liver transplantation.
Cedars Sinai Medical Center
Mazen Noureddin, MD
Dr. Mazen Noureddin is the director of Cedars-Sinai’s Fatty Liver Program.
The Fatty Liver Program at Cedars-Sinai has many breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitisn (NASH), including those with advanced fibrosis and cirrhosis.
The research of Mazen Noureddin, MD, focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new imaging modalities and exploring new treatments.
New York University - Langone
Ira Jacobson, MD
Dr. Ira Jacobson is the director of the Hepatology department at NYU Langone.
Dr. Jacobson is a fellow of several major organizations, including the American College of Physicians, the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the American College of Gastroenterology, and a member of the European Association for the Study of the Liver. He is a past president of the New York Society for Gastrointestinal Endoscopy and the New York Gastroenterological Association.
Holly Lofton, MD
Dr. Lofton is an integral part of NYU’s Weight Management Program. In my practice, I combine scientifically proven weight loss techniques with medications and behavior modification to fit each patient’s needs. I designed the New You™ program to help people obtain results while learning about incorporating nutrition into a healthy lifestyle.
Methodist Health System
Parvez Mantry, MD
Dr. Mantry is the Medical Director at the Liver Institute within Methodist Health System.
Dr. Mantry served as the designated UNOS primary transplant physician and director of transplant hepatology at the University of Rochester Medical Center. Dr. Mantry’s areas of expertise include viral hepatitis, hepatocellular carcinoma, and autoimmune and cholestatic liver diseases. His experience in the area of liver transplantation at a high-volume transplant center is well recognized.